Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration
| Autor: | Achim Gass, Kerstin Bendfeldt, James S. Babb, Jochen G. Hirsch, Ludwig Kappos, Iris-Katharina Penner, Lutz Achtnichts, Yvonne Naegelin, Oded Gonen, Michael Amann, D. J. Rigotti |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male In vivo magnetic resonance spectroscopy Pathology medicine.medical_specialty Magnetic Resonance Spectroscopy Population Sensitivity and Specificity Severity of Illness Index Gastroenterology Article Diagnosis Differential Lesion Internal medicine Severity of illness medicine Humans Radiology Nuclear Medicine and imaging Longitudinal Studies education Brain Chemistry Aspartic Acid education.field_of_study Expanded Disability Status Scale medicine.diagnostic_test business.industry Multiple sclerosis Reproducibility of Results Magnetic resonance imaging General Medicine Multiple Sclerosis Chronic Progressive medicine.disease Magnetic Resonance Imaging Female Protons Differential diagnosis medicine.symptom business Biomarkers |
| Zdroj: | European Journal of Radiology. 82:e848-e852 |
| ISSN: | 0720-048X |
| Popis: | To examine whether clinically benign multiple sclerosis patients (BMS) show similar losses of their global N-acetylaspartate (NAA) neuronal marker relative to more clinically disabled patients of similar disease duration.The whole-brain NAA concentration (WBNAA) was acquired with whole-head non-localizing proton MR spectroscopy. Fractional brain parenchymal volume (fBPV), T2 and T1 lesion loads, were obtained from the MRI in: (i) 24 BMS patients: 23.1 ± 7.2 years disease duration, median Expanded Disability Status Scale (EDSS) score of 2.0 (range: 0-3); (ii) 26 non-benign MS patients (non-BMS), 24.5 ± 7.4 years disease duration, median EDSS of 4.0 (range: 3.5-6.5); (iii) 15 healthy controls.Controls' 12.4 ± 2.3mM WBNAA was significantly higher than the BMS's and non-BMS's 10.5 ± 2.4 and 9.9 ± 2.1mM (both p0.02), but the difference between the patients' groups was not (p0.4). Likewise, the controls' 81.2 ± 4.5% fBPV exceeded the BMS and non-BMS's 77.0 ± 5.8% and 76.3 ± 8.6% (p0.03), which were also not different from one another (p0.7). BMS patients' T1-hypointense lesion load, 2.1 ± 2.2 cm(3), was not significantly different than the non-BMS's 4.1 ± 5.4 cm(3) (p0.08) and T2-hyperintense loads: 6.0 ± 5.7 cm(3) and 8.7 ± 7.8 cm(3), were also not different (p0.1).WBNAA differentiates normal controls from MS patients but does not distinguish BMS from more disabled MS patients of similar disease duration. Nevertheless, all MS patients who remain RR for 15+ years suffered WBNAA loss similar to the average RR MS population at fourfold shorter disease duration suggesting relative global neuronal sparing or leveling-off of the neurodegeneration rate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect